Simon Hester
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- SARS-CoV-2 and COVID-19 Research 3
- COVID-19 Clinical Research Studies 1
-
- Thermal Regulation in Medicine 1
Simon Hester
13 papers receiving 1.7k citations
Simon Hester's Hit Papers
Peers
Comparison fields: 5 of 103
- Infectious Diseases 965
- Applied Microbiology and Biotechnology 50
- Neurology 345
- Internal Medicine 56
- Obstetrics and Gynecology 87
Countries citing papers authored by Simon Hester
This map shows the geographic impact of Simon Hester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Hester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Hester more than expected).
Fields of papers citing papers by Simon Hester
This network shows the impact of papers produced by Simon Hester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Hester. The network helps show where Simon Hester may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2019 | 134 | |
| 7 | 2023 | 83 | |
| 8 | 2023 | 24 | |
| 9 | 2024 | 23 | |
| 10 | 2024 | 6 | |
| 11 | 2025 | 5 | |
| 12 | 2025 | 2 | |
| 13 | 2013 | 1 |
About Simon Hester
Simon Hester is a scholar working on Infectious Diseases, Critical Care and Intensive Care Medicine, Neurology, Cardiology and Cardiovascular Medicine and Surgery, having authored 13 papers that have together received 1.8k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), Thermal Regulation in Medicine (1 paper), COVID-19 Clinical Research Studies (1 paper), Cardiac, Anesthesia and Surgical Outcomes (1 paper), Long-Term Effects of COVID-19 (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (965 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (345 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (87 citations). Simon Hester has collaborated with scholars based in United Kingdom, Australia and Indonesia. Their work appears in journals such as The Lancet, Critical Care Medicine, The Lancet Diabetes & Endocrinology, Nature Communications and The Lancet Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.